Discover
CMPS
COMPASS Pathways plc
13.38
1 x 13.26
8 x 13.60
bid
ask
+
0.20
1.52%
8 @ 04:00 PM
13.26 -0.12 (0.90%)
| Ytd | 93.91% | |
| 1y | 208.29% |
13.20
day range
13.69
3.97
52 week range
15.40
| Open | 13.48 | Prev Close | 13.18 | Low | 13.20 | High | 13.69 | Mkt Cap | 1.81B |
| Vol | 0.00 | Avg Vol | 4.06M | EPS | -3.15 | P/E | -4.25 | Forward P/E | -9.20 |
| Beta | 2.50 | Short Ratio | 3.15 | Inst. Own | 71.49% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-30 | 50-d Avg | 12.59 | 200-d Avg | 8.42 | 1yr Est | 23.75 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-03 | 2026-09 | -0.41 | N/A | N/A | N/A |
| 2026-08-05 | 2026-06 | -0.39 | -1.88 | -1.49 | -384.37% |
| 2026-05-13 | 2026-03 | -0.45 | -0.3 | 0.15 | 33.33% |
| 2026-03-24 | 2025-12 | -0.41 | -0.59 | -0.18 | -43.90% |
| 2025-11-04 | 2025-09 | -0.4 | -0.38 | 0.02 | 5.00% |
| 2025-07-31 | 2025-06 | -0.37 | -0.38 | -0.01 | -2.70% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-08-06 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-08-06 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-08-06 | B. Riley Securities | Upgrade | Buy | Buy |
| 2026-07-27 | Wells Fargo | Upgrade | Equal-Weight | |
| 2026-07-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-09-25 | ATAI LIFE SCIENCES NV | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2024-10-23 | GOLDSMITH GEORGE JAY | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2026-03-25 | LOXAM TERI | Chief Financial Officer | 152.00K | Stock Award(Grant) |
| 2024-10-23 | MALIEVSKAIA EKATERINA | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2026-03-25 | NATH KABIR | Chief Executive Officer | 366.99K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Deep Track Capital, Lp | 12.16M | 162.72M | 9.01% |
| 2026-03-30 | RTW Investments LP | 10.63M | 142.26M | 7.88% |
| 2026-03-30 | Marshall Wace LLP | 4.04M | 54.03M | 2.99% |
| 2026-03-30 | Tang Capital Management, LLC | 4.00M | 53.55M | 2.97% |
| 2026-03-30 | BIT Capital GmbH | 3.49M | 46.71M | 2.59% |
| 2026-03-30 | ARK Investment Management, LLC | 3.30M | 44.17M | 2.45% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | ARK ETF Trust-ARK Genomic Revolution ETF | 3.25M | 43.51M | 2.41% |
| 2026-06-29 | iShares Trust-iShares Biotechnology ETF | 772.94K | 10.34M | 0.57% |
| 2026-04-29 | Columbia Funds Series Trust I-Columbia Small Cap Value Discovery Fund | 420.91K | 5.63M | 0.31% |
| 2026-06-29 | AdvisorShares Trust-AdvisorShares Psychedelics ETF | 359.65K | 4.81M | 0.27% |
| 2026-03-30 | ROYCE FUND-Royce Smaller-Companies Growth Fund | 249.00K | 3.33M | 0.18% |
| 2026-03-30 | Simplify Exchange Traded Funds-Simplify Propel Opportunities ETF | 159.05K | 2.13M | 0.12% |